Loading…
Loading…
Dongcheng District — a core-function district of Beijing with concentrated medical, research and market resources but limited industrial land — is using targeted fiscal grants rather than land/manufacturing incentives to capture a slice of the pharma/health value chain: TCM digitalisation, product-innovation commercialisation, AI-enabled digital-health platforms, and innovative-medicine R&D. The measure explicitly implements Beijing municipal-level direction (the 2024-2026 Beijing Medical-Health Synergistic Innovation Action Plan) at district scale, following the same management-committee/science-and-technology-commission issuance pattern as the district's November 2025 general tech-innovation subsidy package (2025-11-12-china-dongcheng-district-tech-innovation-fiscal-support) and sitting alongside the broader November 2025 Beijing-municipal medical-device package (2025-11-24-china-beijing-medical-device-industry-support-measures).
architecture (municipal medical-device package + district-level TCM/ digital-health package), increasing the effective subsidy ceiling available to firms locating in Dongcheng.
governments running overlapping biopharma industrial-policy schemes (Hainan, Beijing BDA, Beijing municipal, now Dongcheng), each disclosing its own funding caps — relevant to WTO subsidy-notification and Section 301-style overcapacity arguments against Chinese biopharma exports.
Beijing-municipal medical-device package, or whether the schemes are mutually exclusive by registration district.
round opens (funding levels above are caps, not confirmed spend).